Rapamycin + Metformin Combination

The combination of rapamycin and metformin represents an emerging approach in longevity research, targeting complementary cellular pathways associated with aging. Studies suggest that rapamycin's mTOR inhibition combined with metformin's AMPK activation may provide synergistic benefits for metabolic health and cellular maintenance. Animal studies have shown promising results, with some research indicating the combination may be more effective than either drug alone for extending lifespan and improving healthspan markers.

However, this combination remains largely experimental for longevity purposes, with limited human trial data specifically examining their combined use for anti-aging. Most evidence comes from studies of each drug individually, along with theoretical frameworks suggesting complementary mechanisms. The combination carries significant risks, as both drugs have substantial side effect profiles and potential interactions. Rapamycin can suppress immune function and cause metabolic changes, while metformin may cause gastrointestinal issues and, rarely, lactic acidosis.

People considering this combination typically work with physicians experienced in longevity medicine, as it requires careful monitoring of blood work, immune function, and metabolic parameters. The approach is most commonly seen among advanced biohackers and patients in specialized longevity clinics, rather than mainstream medical practice. Research continues into optimal dosing regimens and patient selection criteria for this combination therapy.